Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
2001 1
2004 1
2007 2
2008 2
2009 1
2010 2
2016 2
2019 1
2020 1
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Managing genomic variant calling workflows with Swift/T.
Ahmed AE, Heldenbrand J, Asmann Y, Fadlelmola FM, Katz DS, Kendig K, Kendzior MC, Li T, Ren Y, Rodriguez E, Weber MR, Wozniak JM, Zermeno J, Mainzer LS. Ahmed AE, et al. Among authors: weber mr. PLoS One. 2019 Jul 9;14(7):e0211608. doi: 10.1371/journal.pone.0211608. eCollection 2019. PLoS One. 2019. PMID: 31287816 Free PMC article.
Adaptation of energy metabolism in breast cancer brain metastases.
Chen EI, Hewel J, Krueger JS, Tiraby C, Weber MR, Kralli A, Becker K, Yates JR 3rd, Felding-Habermann B. Chen EI, et al. Among authors: weber mr. Cancer Res. 2007 Feb 15;67(4):1472-86. doi: 10.1158/0008-5472.CAN-06-3137. Cancer Res. 2007. PMID: 17308085
Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis.
Felding-Habermann B, Lerner RA, Lillo A, Zhuang S, Weber MR, Arrues S, Gao C, Mao S, Saven A, Janda KD. Felding-Habermann B, et al. Among authors: weber mr. Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17210-5. doi: 10.1073/pnas.0407869101. Epub 2004 Nov 24. Proc Natl Acad Sci U S A. 2004. PMID: 15563590 Free PMC article.
Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S, Gorton S, Pautret V, Weber MR, Woytowitz D. Lynch TJ, et al. Among authors: weber mr. J Clin Oncol. 2010 Feb 20;28(6):911-7. doi: 10.1200/JCO.2009.21.9618. Epub 2010 Jan 25. J Clin Oncol. 2010. PMID: 20100966 Clinical Trial.
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, Dakhil S, Hermann RC, Lynch TJ, Weber MR. Khambata-Ford S, et al. Among authors: weber mr. J Clin Oncol. 2010 Feb 20;28(6):918-27. doi: 10.1200/JCO.2009.25.2890. Epub 2010 Jan 25. J Clin Oncol. 2010. PMID: 20100958 Clinical Trial.
17 results